Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
about
The gut hormones in appetite regulationGlucagon-like peptide analogues for type 2 diabetes mellitusRegulation of glucose homeostasis by GLP-1SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectivesCardiovascular Effects of Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and futureA Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes MellitusEmerging utility of once-weekly exenatide in patients with type 2 diabetesIncretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitorsTreatment of prediabetesIncretin physiology and pathophysiology from an Asian perspectiveExenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectivesA clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyondAdverse Effects of GLP-1 Receptor AgonistsAn Overview of Current Regulatory Requirements for Approval of Biosimilar InsulinsGLP-1 receptor agonists: a review of head-to-head clinical studiesObesity pharmacotherapy: current perspectives and future directionsAssessment of pancreatic β-cell function: review of methods and clinical applicationsThe Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in KoreaParkinson's disease, insulin resistance and novel agents of neuroprotectionGLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependenceImpact of postprandial glycaemia on health and prevention of diseaseBasal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingCan medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?Action and therapeutic potential of oxyntomodulinPhysiology of proglucagon peptides: role of glucagon and GLP-1 in health and diseaseUpdate on the treatment of type 2 diabetes mellitusTreatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonistsEfficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitusThe short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United StatesPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.The future role of gut hormones in the treatment of obesityThe pharmacological treatment and management of obesity.Exenatide once weekly: opportunities in the primary care setting.Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trialExendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in micePathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.Liraglutide and obesity: a review of the data so far.Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.
P2860
Q21296779-5CD46B8A-EDC5-451A-A191-65B707492847Q24235918-BE346A61-2222-4540-BE7F-6C652F5CA5B0Q24563430-6D3D65F5-CBCE-4018-A7A8-32F3D0DE8224Q26746901-8C7F9E48-D658-4D28-9BDE-CB304499CC62Q26749495-B9D06D53-A2E3-4777-9047-BC175A37B3DFQ26752699-15E48115-04CF-43DB-ADD5-044F9837F05AQ26765155-95D08D35-2FCC-4EDC-B04A-DBB2A73A1A2CQ26777320-BC1193D8-6B12-44CD-BD10-B46C8815B215Q26778608-A8D0F044-FAD5-4807-86D8-1DD6391FAAA8Q26783350-5505BBEA-69D6-47FC-B991-43AF52AD1B9CQ26784623-B10C518D-9574-4F58-8107-FCCBF1463D91Q26797236-08374CAE-4917-4CD7-A14B-FDC12974627CQ26799389-F7E0B76A-020F-42E9-9E2B-C32DD49451B5Q26801346-7DE51990-E62F-40FF-83C9-2C352BC2CDA0Q26823562-C88C3D24-1744-4AC6-9F47-6C809DB6EE7FQ26823768-D141E6E0-EA7A-49E7-A0D4-FE5E06F1DA91Q26828559-E72456AB-92C5-4DA0-85ED-71ADE4D499DAQ26829445-82837F68-5C1A-47AD-89DA-54BF7FDB8F58Q26852590-1E023BF0-CA8A-426E-A1BC-CEE75E4CF7D9Q26853311-39F11CBA-B823-4595-9477-045169E2EB0BQ26858990-74A55522-5846-4FD4-8089-FEE9B339B16FQ26862823-5A347726-1EAA-4C9C-8C18-3FB34291228BQ26992979-FDCEFE17-E455-4B7E-9B5D-82A9636119BFQ27015789-DCB8A0CF-87CA-4F24-BA9A-18384A14E911Q27025870-B6A44B54-1E58-4FF0-9E32-424F6D138196Q27027920-E5625751-7B64-4555-BB4D-B6901BFAF558Q28073342-F2388A0D-C586-434B-9BF8-CCA7FB1E7521Q28077026-5A6BF389-0BC0-43FC-80F7-74BFDC044F4BQ28088578-2244A1D8-87DD-45AA-9E07-8051497E4491Q28545766-4A932EDA-108D-49EE-A82C-7AE03B09A8D5Q30249371-B6420CE3-87FC-4747-BED7-05DA27E6B0FDQ30357431-1269AF18-6EC4-44BE-8E02-D8578F41AFFFQ30399340-FFCA380A-E6F5-4B9F-B3CF-1C359D96D1EDQ30431639-2D18AE49-AE31-4C3D-A2D6-DE8AEB7CD5ECQ30489980-D246B5FE-BFCC-4BF7-AA65-3AE920A77CEFQ30531048-C32F1B2C-0367-4813-93AD-1DC4A0764021Q30597265-DCB70606-9725-42F5-AF22-4485AA9D65C8Q30643065-4DAFEC03-AF11-4DFA-99E2-E9E3778A9D19Q30924982-C568A39A-A1DE-4B90-B806-F5BB3ED9A109Q31066859-F77EDCE1-5EE5-461C-AD66-B61320F330E2
P2860
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Exenatide once weekly versus t ...... n-label, non-inferiority study
@ast
Exenatide once weekly versus t ...... n-label, non-inferiority study
@en
Exenatide once weekly versus t ...... n-label, non-inferiority study
@nl
type
label
Exenatide once weekly versus t ...... n-label, non-inferiority study
@ast
Exenatide once weekly versus t ...... n-label, non-inferiority study
@en
Exenatide once weekly versus t ...... n-label, non-inferiority study
@nl
prefLabel
Exenatide once weekly versus t ...... n-label, non-inferiority study
@ast
Exenatide once weekly versus t ...... n-label, non-inferiority study
@en
Exenatide once weekly versus t ...... n-label, non-inferiority study
@nl
P2093
P3181
P1433
P1476
Exenatide once weekly versus t ...... n-label, non-inferiority study
@en
P2093
David M Kendall
Dongliang Zhuang
Kristin Taylor
Lisa Porter
Michael Trautmann
P304
P3181
P356
10.1016/S0140-6736(08)61206-4
P407
P577
2008-10-04T00:00:00Z